Evidence map›Paper›PMID 30188788›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key.

Manuela Tiako Meyo, Jérôme Alexandre, François Goldwasser, Benoit Blanchet

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Dose optimization during drug development: whether and when to optimize.Journal of the National Cancer Institute · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Manuela Tiako MeyoManuela Tiako Meyo, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, and Cancer Research and Personalized Medicine, Paris, France; Jérôme Alexandre and François Goldwasser, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Cancer Research and Personalized Medicine; and Cochin Institute, Institut National de la Santé et de la Recherche Médicale U1016, Paris, France; and Benoit Blanchet, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Cancer Research and Personalized Medicine; and University of Paris Descartes, Université Sorbonne Paris Cité, Paris, France.
Jérôme AlexandreManuela Tiako Meyo, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, and Cancer Research and Personalized Medicine, Paris, France; Jérôme Alexandre and François Goldwasser, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Cancer Research and Personalized Medicine; and Cochin Institute, Institut National de la Santé et de la Recherche Médicale U1016, Paris, France; and Benoit Blanchet, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Cancer Research and Personalized Medicine; and University of Paris Descartes, Université Sorbonne Paris Cité, Paris, France.
François GoldwasserManuela Tiako Meyo, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, and Cancer Research and Personalized Medicine, Paris, France; Jérôme Alexandre and François Goldwasser, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Cancer Research and Personalized Medicine; and Cochin Institute, Institut National de la Santé et de la Recherche Médicale U1016, Paris, France; and Benoit Blanchet, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Cancer Research and Personalized Medicine; and University of Paris Descartes, Université Sorbonne Paris Cité, Paris, France.
Benoit BlanchetManuela Tiako Meyo, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, and Cancer Research and Personalized Medicine, Paris, France; Jérôme Alexandre and François Goldwasser, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Cancer Research and Personalized Medicine; and Cochin Institute, Institut National de la Santé et de la Recherche Médicale U1016, Paris, France; and Benoit Blanchet, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Cancer Research and Personalized Medicine; and University of Paris Descartes, Université Sorbonne Paris Cité, Paris, France.
Hôpital Cochin · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantAbiraterone AcetateAndrostenesDrug MonitoringHumansMaleProspective StudiesabirateroneAbiraterone AcetateAndrostenes

Identifiers

PMID30188788
OpenAlexW2890768803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.